

UMR Medical Policy Update Bulletin *Quick View*: May 2025



A list of recently approved, revised, and/or retired Medical Policies and/or Medical Benefit Drug Policies is provided below for your reference. **For a comprehensive summary of the latest updates, refer to the [Medical Policy Update Bulletin: May 2025](#).**

Medical Policy Updates

Policy Title	Status	Effective Date
Cell-Free Fetal DNA Testing	Revised	Jun. 1, 2025
Durable Medical Equipment, Orthotics, Medical Supplies, and Repairs/Replacements	Updated	May 1, 2025
Enteral Nutrition (Oral and Tube Feeding)	Revised	Jun. 1, 2025
Facet Joint and Medial Branch Block Injections for Spinal Pain	Updated	May 1, 2025
Home Hemodialysis	Updated	May 1, 2025
Mobility Devices, Options, and Accessories	Replaced	May 1, 2025
Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions	Revised	Jun. 1, 2025
Negative Pressure Wound Therapy	Revised	Jul. 1, 2025
Orthognathic (Jaw) Surgery	Updated	May 1, 2025
Patient Lifts	Retired	May 1, 2025
Pediatric Gait Trainers and Standing Systems	Retired	May 1, 2025
Pneumatic Compression Devices	Revised	Jun. 1, 2025
Prostate Surgeries and Interventions	Revised	Jul. 1, 2025
Proton Beam Radiation Therapy	Revised	Jun. 1, 2025
Respiratory Pathogen Nucleic Acid Detection Testing	New	Jun. 1, 2025
Speech Generating Devices	Replaced	May 1, 2025
Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins	Revised	Jul. 1, 2025
Walkers	Updated	Jun. 1, 2025

Medical Benefit Drug Policy Updates

Policy Title	Status	Effective Date
Adakveo® (Crizanlizumab-Tmca)	Revised	Jun. 1, 2025
Aduhelm® (Aducanumab-Avwa)	Retired	Jun. 1, 2025
Cosentyx® (Secukinumab)	Updated	May 1, 2025
Edaravone	Revised	Jun. 1, 2025
Ilumya® (Tildrakizumab-Asmn)	Revised	Jun. 1, 2025
Maximum Dosage and Frequency	Revised	May 1, 2025
Medical Therapies for Enzyme Deficiencies	Revised	Jun. 1, 2025
Orencia® (Abatacept) Injection for Intravenous Infusion	Updated	May 1, 2025

Policy Title	Status	Effective Date
Qalsody® (Tofersen)	Revised	Jun. 1, 2025
Reblozyl® (Luspatercept-Aamt)	Revised	Jun. 1, 2025
RNA-Targeted Therapies (Amvuttra® and Onpattro®)	Revised	Jun. 1, 2025
Spinraza® (Nusinersen)	Revised	Jun. 1, 2025
Uplizna® (Inebilizumab-Cdon)	Updated	May 1, 2025
Veopoz® (Pozelimab-Bbfg)	Revised	Jun. 1, 2025

General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

UMR is a wholly owned subsidiary of UnitedHealthcare, a part of UnitedHealth Group. UMR is a third-party administrator (TPA) for self-funded plans.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UMR Medical Policies and Medical Benefit Drug Policies is available at UHCprovider.com/policies > For Commercial Plans > [UnitedHealthcare | UMR Medical & Drug Policies](#).